Reporting quality of clinical studies using mesenchymal stromal cell therapy for the prevention or treatment of bronchopulmonary dysplasia

When a baby is born extremely prematurely, their lungs are often too immature to function on their own. This condition, known as bronchopulmonary dysplasia, can lead to lifelong breathing problems and is a major cause of illness for the smallest newborns. For years, scientists have looked for a way to help these fragile lungs heal. One promising approach involves using mesenchymal stromal cells, a type of living cell found in the body that can calm inflammation and help tissue repair itself. These cells have shown great potential in laboratory experiments and animal studies, leading researchers to begin testing them in human babies. However, for any new medical treatment to become a standard part of care, doctors and scientists must be able to understand exactly what was given to the patient. If the details of how the cells were grown, prepared, and stored are missing, it becomes impossible to know if the treatment worked because of the cells themselves or because of something else in the process.

A team of researchers set out to examine how well scientists have been sharing these crucial details in recent clinical trials. They gathered ten studies that had already tested these cell therapies in babies with or at risk of lung disease. The researchers did not test the cells themselves; instead, they acted as auditors, checking the published reports of these trials against a new, strict set of rules for how such studies should be described. These rules, established by a global group of experts in 2025, list forty specific pieces of information that must be included to ensure the science is clear and reproducible. The team wanted to see if the studies that had already been published, which were written before these new rules existed, happened to include all the necessary information on their own.

The findings revealed a significant gap between what is needed and what is currently being shared. The researchers found that nearly every study was missing key details about the cells being used. In fact, only four out of the ten studies provided enough information to cover three-quarters of the required reporting items. Four other studies were even less complete, reporting on less than forty percent of the necessary details. While the studies were generally good at stating how the cells were delivered to the baby and how many cells were used, they were very poor at describing the environment in which the cells were grown. For instance, none of the studies mentioned how long the cells were frozen before use, and none described the specific oxygen levels or the type of liquid nutrients used to grow them.

This lack of detail matters because the way cells are manufactured is just as important as the cells themselves. Just as a baker cannot recreate a cake without knowing the exact ingredients, temperature, and mixing time, a doctor cannot understand a cell therapy without knowing the exact conditions under which the cells were prepared. The researchers noted that factors like the type of nutrients used or the length of time cells are stored can change how the cells behave and whether they can actually help the patient. Because these details were missing, it is difficult to combine the results of different studies to see the full picture of whether the treatment works. The authors conclude that while the biological idea behind these therapies is sound, the scientific record is currently too incomplete to move forward confidently. They urge future researchers to be much more thorough in their reporting, ensuring that every step of the process is described clearly so that these treatments can be properly evaluated and eventually become a reliable help for premature infants.